Moderna told reporters at its Marlborough, Massachusetts plant this week that it is on track and ready to manufacture several thousand doses of intismeran autogene, the personalised cancer vaccine it is developing with Merck, as the partners prepare to file a marketing application with the FDA by the end of this year. The plant is slated to become the global supply base for the product in 2027, subject to regulatory approval, and has been producing clinical trial material since September 2025. Moderna recently brought Juan Andres back as chief operating officer to lead its manufacturing organisation ahead of the potential launch.
The clinical case is already public. In the Phase 3 INTerpath-001 trial in high risk melanoma after surgery, intismeran combined with Merck’s Keytruda cut the risk of recurrence or death by 42 percent (hazard ratio 0.58) against Keytruda alone, with the risk of distant metastasis or death down 38 percent. No personalised cancer vaccine has ever been approved, and Moderna’s chief executive has said the aim is full approval in 2027, which depends on the filing landing by year end and on the FDA’s review clock once it does.
Manufacturing is the open question the plant visit was staged to answer. Each dose of intismeran is built for a single patient from the mutations in that patient’s own tumour, encoding up to 34 neoantigens in one mRNA product, so there is no batch scale economy of the kind conventional vaccines enjoy. Moderna has not disclosed commercial production capacity in detail, per patient turnaround times or cost of goods, and those three numbers, alongside the filing date itself, are what will decide whether a 2027 launch is a plan or an aspiration.